Evaxion biotech announces publication of clinical data of evx-01 heading into phase 2b in collaboration with merck

Copenhagen, denmark, jan. 26, 2022 (globe newswire) -- evaxion biotech a/s (nasdaq: evax), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper on personalized therapy with evx-01 in patients with metastatic melanoma in the open access, peer-reviewed journal oncoimmunology.
EVAX Ratings Summary
EVAX Quant Ranking